Lung Cancer Stage IV Clinical Trial
— LUCACRIMUNOOfficial title:
The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer
Lung cancer remains one of the most commonly diagnosed oncological diseases worldwide and the first in terms of mortality. Although immune checkpoint inhibitors form the backbone of current metastatic non-small cell lung cancer treatments, there is still no ideal predictive marker for its efficacy and patients still achieve suboptimal results in overall response and survival. While immune checkpoint inhibitors are known to shift systemic anti-tumor immune response from suppression to stimulation in some patients, the investigators hypothesize that this effect can be further enhanced by cryotherapy, especially in "cold" tumors. If proven successful, cryotherapy in combination with immunotherapy, could potentiate a more powerful immune response compared to systemic therapy alone, improve overall response rate, patients' survival without disease progression, and overall survival. The investigators, therefore, aim to use combined local tumor cryotherapy, combined with immune checkpoint inhibitor therapy to induce and evaluate systemic anti-tumor T lymphocyte response and achieve improved non-small cell lung cancer patient outcomes than with immunotherapy alone.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | March 31, 2026 |
Est. primary completion date | March 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Patients with Eastern Cooperative Oncology Group (ECOG) performance score 0 - 1; - Patients with histologically confirmed metastatic non-small cell lung cancer and PD-L1 expression on tumor cells was evaluated; - CT examination shows measurable tumor formations according to the RECIST 1.1 criteria; - Primary lung tumor or metastasis accessible to flexible bronchoscopy; - Patients may have received surgery, adjuvant or neoadjuvant chemotherapy prior to the study if it was completed at least 12 months before relapse; - Patients informed about the purpose and course of the study and provided a written consent to participate. Exclusion Criteria: - Patients who refused to participate in the clinical trial and did not sign the informed consent form; - Men and women under the age of 18, pregnant women; - Patients belonging to a vulnerable social group; - High risk of general anesthesia, defined as American Society of Anesthesiologists (ASA) class 4 - 6; - Documented allergy to medications used during general and local anesthesia, systemic cancer treatment; - Patients previously treated with immune checkpoint inhibitors; - EGFR mutations or ALK translocations have been identified in patients; - Patients with previously diagnosed autoimmune diseases, active viral hepatitis, uncontrolled human immunodeficiency virus (HIV) infection or untreated tuberculosis; - Patients treated with immunosuppressive drugs, systemic corticosteroids, with equivalent doses of prednisolone exceeding 10 mg/day; - Patients with an increased risk of bleeding during an interventional procedure; - Acute untreated conditions that would make it impossible to perform an interventional lung procedure. |
Country | Name | City | State |
---|---|---|---|
Lithuania | Lithuanian University of Health Sciences | Kaunas |
Lead Sponsor | Collaborator |
---|---|
Lithuanian University of Health Sciences | Research Council of Lithuania |
Lithuania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in T Lymphocyte Count and Function in Response to Cryotherapy and Immunotherapy | Changes in T lymphocyte counts and function in peripheral venous blood assessed via flow cytometry | 6 weeks | |
Secondary | Necrotic cancer cell death | A change in the concentration of High mobility group box 1 protein (HMGB-1) in venous blood | 6 weeks | |
Secondary | The influence of immune cell infiltration in tumor tissue on subsequent cryotherapy and immunotherapy treatment | Number of tumor-infiltrating CD4 and CD8 lymphocytes in non-small cell lung cancer biopsy material by immunohistochemistry. | 1 day | |
Secondary | Objective response rate | Assessed according to RECIST and iRECIST criteria | 1 year | |
Secondary | Progression-free survival | The time from the first cycle of systemic treatment to radiologically confirmed disease progression | 1 year | |
Secondary | Overall survival | The time from the first cycle of systemic treatment to death from any cause | 1 year | |
Secondary | Safety of bronchoscopic cryotherapy and immunotherapy | Documentation and assessment of adverse treatment events according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. | 1 year | |
Secondary | Changes in T Lymphocyte Function in Response to Cryotherapy and Immunotherapy | Changes in T lymphocyte function in peripheral venous blood assessed via RNA expression | 6 weeks | |
Secondary | Changes in T Lymphocyte Effector Function in Response to Cryotherapy and Immunotherapy | Changes in T lymphocyte effector function in peripheral venous blood evaluated via cytokine panels | 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03668496 -
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
|
Phase 3 | |
Active, not recruiting |
NCT03322072 -
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating
|
N/A | |
Recruiting |
NCT05497973 -
Psychosocial eHealth in Advanced Lung Cancer
|
N/A | |
Recruiting |
NCT06076005 -
Lung Cancer ID (Identity) Study
|
||
Recruiting |
NCT05860296 -
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05311709 -
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
|
Phase 2 | |
Completed |
NCT04825912 -
Resilience Measurement in Older Adults With Late-Stage Lung Cancer
|
N/A | |
Completed |
NCT03529851 -
Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients
|
N/A | |
Completed |
NCT03558165 -
Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
|
||
Completed |
NCT03076164 -
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03153358 -
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
|
Phase 2 | |
Recruiting |
NCT04595734 -
Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
|
||
Recruiting |
NCT04519983 -
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
|
Phase 2 | |
Not yet recruiting |
NCT05701384 -
Lazertinib 160mg in EGFR T790M NSCLC
|
Phase 2 | |
Withdrawn |
NCT03409341 -
Personalizing Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT03728361 -
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06024941 -
Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04669223 -
Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion
|
N/A | |
Recruiting |
NCT05996263 -
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
|
||
Completed |
NCT04057196 -
Self-System Therapy for Older Adults With Lung Cancer
|
N/A |